NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versu... ( New Analysis of the 104 ABPM Stu...)

NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versus Naproxen

Date:11/12/2008

New Analysis of the 104 ABPM Study Presented at the American Heart

Association

http://www.nicox.com

SOPHIA ANTIPOLIS, France, November 12 /PRNewswire-FirstCall/ -- NicOx S.A. (Euronext Paris: COX) today announced that a new analysis of the data from the 104 Ambulatory Blood Pressure Monitoring (ABPM) study for naproxcinod was presented yesterday at the American Heart Association Scientific Sessions 2008, in New Orleans, USA. This ABPM pilot study in hypertensive volunteers was designed to compare the 24-hour blood pressure profiles of naproxcinod 750 mg bid and naproxen 500 mg bid. Naproxcinod is NicOx' lead investigational product and the first compound in the new Cyclooxygenase-Inhibiting Nitric Oxide-Donating (CINOD) class of anti-inflammatory agents.

This new post hoc analysis was accepted by the American Heart Association scientific panel and compared the mean 24-hour systolic blood pressure (SBP) as measured by ABPM in the two groups (i.e. naproxcinod vs. naproxen), at the end of the 2 weeks of active treatment. The mean 24-hour SBP showed a difference of 2.4 mmHg (standard error 0.87 mmHg) in favor of naproxcinod as compared to naproxen (p=0.007) after 2 weeks of treatment. Interestingly, for the daytime measurements (the 8 hours following the morning dose), the mean 8-hour SBP showed a difference of 4.4 mmHg (standard error 0.98 mmHg) in favor of naproxcinod as compared to naproxen (p<0.0001) after 2 weeks of treatment.

"It was very interesting and rewarding to share these promising results with the medical community at the American Heart Association Scientific Sessions, which is one of the leading cardiology congresses worldwide," commented Jacques Djian MD, Cardiologist and Vice-President Translational Medicine at NicOx. "This new analysis of the blood pressure data from the 104 study follows the excellent top-line r
'/>"/>

679

GOOD

Page: 1 2 3
Related biology technology :

1. NicOx Reports Results for the First Three Quarters of 2008
2. NicOx Signs Agreement With Capsugel for the Commercial Manufacture of Naproxcinod Oral Capsules
3. NicOx Announces Departure of Damian Marron for CEO Position
4. NicOx Signs Agreement for the Commercial Manufacture of Naproxcinod Drug Substance
5. NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis
6. NicOx to Present at Financial Conferences in New York on November 27, 28 and 29
7. NicOx Opens U.S. Headquarters in New Jersey
8. Potentia Pharmaceuticals Drug Candidate for Age-Related Macular Degeneration Shows Positive Safety Profile in Phase I Clinical Trial
9. Interim Analysis of Top-Line Data From Phase II/III Study Shows Favorable Efficacy & Safety for Cortheras Relaxin in Acute Heart Failure
10. New Research Shows Many Patients with Persistent Cough and Sputum Actually had Airway Obstruction Consistent with COPD
11. Nycomeds Daxas(R) Shows Encouraging Preliminary Results in Phase III COPD Studies

Post Your Comments:

NicOx' Naproxcinod Shows Highly Significant Reduction in Daytime Blood Pressure Versu...( New Analysis of the 104 ABPM Stu...)